Develops oral drugs for obesity and fatty liver disease.
Jun 2026Revenue $3.00K/yrExpenses $4.06M/yr
No trendCash runway ≈ 1 month from Jun 2026
Figures by year
When will Alaunos Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $3.00K and expenses $4.06M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $5.00K | $4.23M | −$4.22M |
| Dec 2024 | $10.0K | $4.82M | −$4.81M |
| Dec 2023 | $5.00K | $34.3M | −$34.3M |
| Dec 2022 | $2.92M | $38.0M | −$35.1M |
| Dec 2021 | $398K | $77.9M | −$77.5M |
| Dec 2020 | $0.00 | $80.4M | −$80.4M |
| Dec 2018 | $146K | $54.1M | −$53.9M |
| Dec 2017 | $6.39M | $59.9M | −$53.5M |
| Dec 2016 | $6.86M | $172M | −$165M |
| Dec 2012 | $800K | $103M | −$102M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.